Prognostic significance of FIGO 2018 staging of loco-regionally advanced cervical cancer (LRACC) with the use of MRI and PET and implications for treatment selection
- Author(s)
- Lin, MY; Mileshkin, L; McNally, O; Kondalsamy-Chennakesavan, S; Narayan, K;
- Journal Title
- Gynecologic Oncology
- Publication Type
- Research article
- Abstract
- INTRODUCTION: The FIGO 2018 staging of cervix cancer recognizes a total of 11 categories of loco-regionally advanced cervix cancer (LRACC). Whilst incorporating imaging is an improvement over clinical staging (FIGO 2009), this had led to more categories of disease which are not prognostically discrete groups. We aimed to analyze survival according to 2018 FIGO stages of cervix cancer and identify isoprognostic groups of patients based on primary tumor volume and nodal status. METHODS: Patients referred for radiotherapy with curative intent between 1996 and 2014 were eligible. Baseline clinico-pathological and follow up information was retrieved from an ethics-approved institutional prospective database. Patients were classified according to FIGO 2018 staging based on histo-pathology, MRI (tumor volume and local compartmental spread assessment) and PET results (nodal spread). Kaplan-Meier method was used to estimate survival at five years. Following survival analysis using recognized prognostic factors, isoprognostic categories were identified and merged to form 5 isoprognostic groups. RESULTS: Seven hundred and forty-four LRACC patients were included. The median (IQR) follow-up was 5.1 (2.6-8.4) yrs. Stage migration occurred in most patients, showing heterogeneous 5 years survival according to 2018 FIGO stages. In contrast progressively worsening prognosis could be demonstrated in the 5 observed isoprognostic clusters (p < 0.002). CONCLUSION/IMPLICATIONS: Prognosis in LRACC depends on the interplay between primary tumor characteristics, type of local spread and nodal disease. A prospective study of survival and patterns of failure according to isoprognostic clusters would be useful to determine the most appropriate treatment modality and estimate survival as well as better patient selection for clinical trials.
- Publisher
- Elsevier
- Keywords
- Female; Humans; *Uterine Cervical Neoplasms/diagnostic imaging/therapy/pathology; Prospective Studies; Patient Selection; Neoplasm Staging; Retrospective Studies; Prognosis; Magnetic Resonance Imaging; Positron-Emission Tomography; Cervix cancer; FIGO staging; Prognostic factors; Radiotherapy; Tumor volume
- Department(s)
- Radiation Oncology
- PubMed ID
- 36521354
- Publisher's Version
- https://doi.org/10.1016/j.ygyno.2022.11.021
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-06-06 06:43:59
Last Modified: 2023-06-06 06:45:18